Paratek’s pneumonia antibiotic succeeds in phase 3 trial

This article was originally published here

A phase 3 study of Paratek Pharmaceuticals’ omadacycline has met its primary and secondary endpoints in the treatment of patients with community-acquired bacterial pneumonia (CABP).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply